Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia

Yetmar, Zachary A.; Khodadadi, Ryan B.; Go, John Raymond; Chesdachai, Supavit; Saleh, Omar M. Abu

doi:10.1007/s10096-023-04575-z

Cited by 9 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23-4.08). This aligns with an abstract that demonstrated ceftriaxone-treated patients (n = 37) with MSSA bacteremia had higher rates of 30-day (8.1% vs. 3.8%) and 90-day (27% vs. 8.6%) treatment failure when compared to a cohort (n = 186) treated with cefazolin and ASPs [20]. Similarly, a small, retrospective study within the veterans affairs system of 71 patients treated with either ceftriaxone or cefazolin for MSSA bacteremia found ceftriaxone to be associated with a higher rate of treatment failure (54.5% vs. 28.9%, p = 0.029), though they only included seven patients with IE [21].…”

Section: Ceftriaxone/cefotaximesupporting

confidence: 87%

Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis

et al. 2023

View full text Add to dashboard Cite

Infective endocarditis (IE) is a rare but increasingly prevalent disease with high morbidity and mortality, requiring antimicrobials and at times surgical intervention. Through the decades of healthcare professionals’ experience with managing IE, certain dogmas and uncertainties have arisen around its pharmacotherapy. The introduction of new antimicrobials and novel combinations are exciting developments but also further complicate IE treatment choices. In this review, we provide and evaluate the relevant evidence focused around contemporary debates in IE treatment pharmacotherapy, including beta-lactam choice in MSSA IE, combination therapies (aminoglycosides, ceftaroline), the use of oral antimicrobials, the role of rifamycins, and long-acting lipoglycopeptides.

show abstract

Section: Ceftriaxone/cefotaximesupporting

confidence: 87%

Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Prior to the introduction of continuous intravenous infusions (CIVs), administration of flucloxacillin for serious Methicillin Sensitive Staphylococcus aureus (MSSA) infection was not logistically practical in the OPAT setting, due to its required dosing frequency of every 4-6 hours to ensure pharmacokinetic/pharmacodynamic (PK-PD) parameters are achieved [1]. Other once daily treatment options, namely ceftriaxone, are not favoured as a first-line treatment option for MSSA bacteraemia compared to anti-staphylococcal penicillins, given concerns of higher risk of treatment failure and conflicting results relating to efficacy in the OPAT setting [2,3]. Continuous antimicrobial infusions are advised within the OPAT good practice recommendations [4] to be used where there are robust drug stability data, such data is published for flucloxacillin [5].…”

Section: Introductionmentioning

confidence: 99%

Clinical Effectiveness of Continuous Infusion Flucloxacillin in the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting in a UK Hospital: A Service Evaluation

Clarkson,

Snape

2024

Antibiotics

View full text Add to dashboard Cite

The availability of stability data for the use of continuous intravenous flucloxacillin in an elastomeric device has enabled the treatment of serious Methicillin Sensitive Staphylococcus aureus (MSSA) in the outpatient parenteral antimicrobial therapy (OPAT) setting. This service review aimed to evaluate current standard of care to establish the clinical effectiveness and complication rates associated with its use since its introduction at our institution. A retrospective review of clinical outcomes and adverse events/complications, was undertaken for all patients who received continuous infusion flucloxacillin for complicated MSSA infection between January 2019 and July 2022 via our OPAT service. Thirty-nine patients were included. An OPAT treatment outcome of ‘Treatment aim attained uncomplicated’ was achieved in 29/39 (74%) patients. Two patients had an OPAT treatment outcome of treatment aim not attained, both of which required unexpected hospital re-admission. An adverse event/complication occurred in 8 patients. There were two relapses in the 12-month follow-up period. Our review supports the assertion that continuous infusion flucloxacillin is clinically effective and well tolerated for the treatment of complicated MSSA infection in the OPAT setting.

show abstract

Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?

Bella

Gatti

Principe

2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia

Cited by 9 publications

References 25 publications

Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis

Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis

Clinical Effectiveness of Continuous Infusion Flucloxacillin in the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting in a UK Hospital: A Service Evaluation

Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?

Contact Info

Product

Resources

About